StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a report published on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reiterated a neutral rating on shares of TRACON Pharmaceuticals in a report on Monday, July 1st.
View Our Latest Analysis on TRACON Pharmaceuticals
TRACON Pharmaceuticals Price Performance
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The firm had revenue of $0.06 million during the quarter.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Featured Stories
- Five stocks we like better than TRACON Pharmaceuticals
- Pros And Cons Of Monthly Dividend Stocks
- How Much Can You Make in Stocks in One Month?
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- This Is the Top Large-Cap Stock Insiders Are Buying
- Basic Materials Stocks Investing
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.